The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMRT followed by pembrolizumab in the adjuvant setting in anaplastic cancer of the thyroid (IMPAACT): Phase II trial adjuvant pembrolizumab after IMRT in ATC.
 
Maria E. Cabanillas
Honoraria - Loxo/Lilly
Consulting or Advisory Role - Bayer; Exelixis; Ignyta; Lilly; Loxo
Research Funding - Eisai; Exelixis; Kura Oncology; Merck; Roche/Genentech
 
Gary Brandon Gunn
No Relationships to Disclose
 
Mark E. Zafereo
Research Funding - Lilly (Inst); Merck (Inst)
 
Rui Jennifer Wang
No Relationships to Disclose
 
Priyanka C. Iyer
No Relationships to Disclose
 
Anastasios Maniakas
No Relationships to Disclose
 
Michael T Spiotto
No Relationships to Disclose
 
Ramona Dadu
Honoraria - Bayer
Consulting or Advisory Role - Exelixis
Research Funding - AstraZeneca (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst)